Biaxin case we are talking about competition in a mature market antibiotics intended for use in the treatment of bacterial infections of the respiratory tract. The case tells the story of how Pfizer's Zithromax stole share dominance established brand, Biaxin Abbott. It comes to understanding the importance of pharmaceutical markets in the consumer (patient) and the (doctor and insurance payer), as well as the effectiveness of pharmacological data. "Hide
by Julie Hennessy Source: Kellogg School Management 4 pages. Publication Date: January 1, 2008. Prod. #: KEL361-PDF-ENG
Related Case Solutions & Analyses:
Governance and Talent Management in a Professional Services Firm
The Bottom-line Benefits of Ethics Code Commitment
Lessons from Pharmaceutical Product Litigation: Merck and the Vioxx Withdrawal Cona & McDarby vs. Merck Video Supplement
ATH MicroTechnologies: Making the Numbers
Critical Competitive Strategy Issues Every Entrepreneur Should Consider Before Going into Business
From Plague to Paradigm: Designing Sustainable Retail Environments
New Leaders for New Schools
Expense Recognition
Procter & Gamble Canada (B): The Canadian MDO
Governance Reform at MCI
